ProgrammableMarketing/springworkstx.com (opens in a new tab)
PDF

Views

  • Plan
  • Roadmap
  • Research

On this page

  • The brief
  • Start here
  • Idea portfolio
  • Effort vs impact
  • This week · 6
  • This quarter · 9
  • Big bets · 3
  • Wildcards · 3
  • How we can help
Generated Oct 26, 2026
  1. Programmable
  2. Playbooks
  3. SpringWorks Therapeutics
SpringWorks Therapeutics logo

growth playbook · Oct 26, 2026

springworkstx.com (opens in a new tab)

SpringWorks Therapeutics growth playbook

Diagnosis

SpringWorks has two approved medicines it describes as first and only in their indications, and its open roles show the focus: a payer and access marketer for OGSIVEO, a West regional sales director, new GOMEKLI territories in New Orleans, Phoenix and Seattle, and a West MSL who also presents to managed care.

The digital front doors have not caught up: the OGSIVEO HCP site has no route for payers, pharmacists or GPOs, the corporate disease pages are still titled as trials, and the NF1 page's GOMEKLI safety section links to the OGSIVEO label.

This playbook fixes those first, then builds pull-through tools, territory launch kits, adult NF1 and pharmacist education, a managed-care evidence summary and Spanish support, before preparing access for a second desmoid option and a shared rare tumors HCP hub. Every item stays within the approved labels and goes through Medical, Legal and Regulatory review.

Growth Score

6/10

Biggest Opportunity

Use owned channels to reach the access audiences and adult NF1 doctors that the new hires are meant to win, while the medicines are still the only approved options for those patients.

Biggest Risk

An investigational competitor in desmoid tumors has an FDA action date in April 2027, and payer coverage can be revisited when it arrives; slow pull-through now would make that harder.

01

Start here

The three moves to make first. Each one is written up in full below.

  1. 1

    Give payers, pharmacists and GPOs their own front door on the OGSIVEO HCP site

    List the approved payer materials that exist today and the gaps.

    High impact First result in 1 quarter
  2. 2

    Point the NF1 page's GOMEKLI safety section to the GOMEKLI label

    Correct the link on the NF1 page.

    High impact First result in 1 day
  3. 3

    Retitle the disease pages from "Trial" to what they are now

    Draft new titles and descriptions for the two pages.

    Medium impact First result in 1 month

02

Your idea portfolio

21 ideas, grouped by when to run them. Open any idea for how to run it: the steps, who to approach, copy you can use, and how to measure it.

  • 6 ideas are marked Unexpected: plays you are unlikely to have tried.

    1 of these are things Programmable can build and run for you.

Every idea placed by the effort it takes against the impact it could have. Quick wins sit top left; select a number to open that idea. The filters below narrow the list by status, timing, category and what Programmable can build.

Effort vs impactEach number is an idea. Select one to open it.
Impact →
Quick wins · 1Big bets · 8Fill-ins · 8Reconsider · 4
Effort →

Showing 21 of 21 ideas

This week 6

Quick wins with a clear first action.

  • 01

    SpringWorks is hiring a payer and access marketer to run "non-personal promotion" for "payers, population-based decision-makers, pharmacists, GPOs". Yet ogsiveo.com/hcp is built only for prescribers: there is no managed-care or pharmacy page, and the Connect With Us form offers only Oncology, Surgery, NP/RN/PA or Other, so a P&T pharmacist or payer has no named way in.

    High impactMedium effort First result in 1 quarter Associate Director

    First action

    List the approved payer materials that exist today and the gaps.

    How to measure it

    Payer and pharmacist contacts from the site

    Now
    –
    Target
    50 a quarter
    By
    2 quarters

    Steps

    1. 1

      Inventory materials

      Approved payer, coding and ordering resources.

      Associate Director, Payer & Access Marketing 1 week

    2. 2

      Design the section

      Dossier request, resources, contact route.

      Omnichannel Marketing Lead 1 week

    3. 3

      Update the form

      Add payer, pharmacist and GPO roles with routing.

      Omnichannel Marketing Lead 3 days

    4. 4

      MLR review

      Every page and form label.

      Medical, Legal and Regulatory review 3 weeks

    5. 5

      Launch

      Link from the HCP navigation and access page.

      Omnichannel Marketing Lead 1 day

    6. 6

      Brief the field

      Account directors and Field Access Managers share the link.

      Associate Director, Payer & Access Marketing 1 week

    7. 7

      Measure

      Requests and contacts by audience type.

      Commercial Operations monthly

    First result
    1 quarter
    Cost
    Agency and review time
    Owner
    Associate Director, Payer & Access Marketing

    Smallest test

    Add the three new roles to the Connect form first and route them to the account team.

    Why it works

    Add a "Managed care and pharmacy" section to the HCP site: an AMCP-format dossier request, the approved value and coding resources already used by the field (such as the ICD-10 flashcard and ordering guide), specialty pharmacy and distribution details, and a contact route to the account team. Add "Payer / PBM", "Health-system or specialty pharmacist" and "GPO / IDN" to the Connect form so those contacts reach the right team. Take every page through MLR before launch.

    Access decision-makers look for a dossier and a contact before they meet anyone. A clear route lets the new non-personal programme start from owned channels and gives the account directors a link to send.

    Ready to use

    ChecklistManaged care section launch list

    [ ] AMCP-format dossier request form
    [ ] Approved coding and ordering resources
    [ ] Specialty pharmacy and distribution details
    [ ] Contact route to account directors
    [ ] Payer / PBM, pharmacist, GPO / IDN options on Connect With Us
    [ ] US-audience gate
    [ ] MLR approval recorded
    [ ] Request tracking by audience

    Risks and how to handle them

    • Promotional rules for payer communications

      Keep content to approved, on-label materials reviewed by MLR.

    • Requests from outside the US

      Gate with a US-audience confirmation as on the rest of the site.

    Evidence

    • HiringAssociate Director, Payer & Access Marketing - US Rare Tumors (OGSIVEO) (Boston hybrid, posted September 14, 2026): will "shape and execute the OGSIVEO value proposition across US market access channels" for "payers, population-based decision-makers, pharmacists, GPOs, and external thought leaders"; will "Head the strategy and execution of non-personal promotion initiatives for market access audiences", drive "pull-through of GPO strategy", build "measurement frameworks", move work through MLR review, and "equip field teams with coordinated value messaging in a more competitive market"; external groups named include "PBMs", "COA, NCODA, ASCO, NCCN".Source
    • Your websiteogsiveo.com HCP site (sitemap checked October 23, 2026): sections for desmoid treatment, overview and data, dosing and management, patient support and access, practice resources, patient profiles, videos and Connect With Us; no page for payers, formulary decision-makers, pharmacists or GPOs. The Connect With Us form lists specialties "Oncology", "Surgery", "NP/RN/PA" and "Other". The access page describes SpringWorks CareConnections, Quick Start and Bridge programs, a commercial copay program, Field Access Managers and specialty pharmacy ordering.Source
    • HiringMedical Science Liaison / Senior MSL - West Region (WA, OR, CA, NV, AZ, HI, AK; board updated October 15, 2026): builds scientific relationships with KOLs "in academic centers and community practices", staffs "disease state booths" at congresses, and serves "as a Medical Affairs lead for disease state and outcomes-based product presentations to managed-care customers".Source
    • News coverageThe FDA accepted Immunome's New Drug Application for varegacestat, an investigational gamma secretase inhibitor for adults with desmoid tumors, with an action date of April 28, 2027. SpringWorks' NF1 page notes that the FDA "approved another drug from the MEK inhibitor class for the treatment of children with NF1-PN".Source
  • 02

    On springworkstx.com's NF1 page, the GOMEKLI Important Safety Information ends "Please see full Prescribing Information", but the link opens the OGSIVEO (nirogacestat) label. The mirdametinib pipeline page already links the right one.

    High impactLow effort First result in 1 day GOMEKLI Brand Lead

    First action

    Correct the link on the NF1 page.

    How to measure it

    Correct PI links

    Now
    –
    Target
    100% of pages
    By
    1 week

    Steps

    1. 1

      Fix the link

      NF1 page.

      Omnichannel Marketing Lead 1 hour

    2. 2

      Audit all pages

      Every PI and ISI link.

      Omnichannel Marketing Lead 1 day

    3. 3

      Review

      Confirm with regulatory.

      Medical, Legal and Regulatory review 2 days

    4. 4

      Add a check

      Monthly automated link test.

      Omnichannel Marketing Lead 1 day

    5. 5

      Document

      Which URL each product uses.

      Omnichannel Marketing Lead 1 hour

    6. 6

      Repeat at label updates

      Re-check when a new PI is posted.

      Omnichannel Marketing Lead each update

    First result
    1 day
    Cost
    $0
    Owner
    GOMEKLI Brand Lead

    Smallest test

    Fix the one link today.

    Why it works

    Change the link to /gomekli-prescribing-info, check every page for other cross-wired label links, and add a monthly link check of all PI and safety links to the site's maintenance list.

    Readers who click for full safety information should get the right label, and fixing it quickly keeps the corporate site consistent with the brand sites.

    Risks and how to handle them

    • Short redirects change later

      Use one named URL per product and test it.

    Evidence

    • Your websiteOn the NF1 page (fetched twice, October 23, 2026), the GOMEKLI Important Safety Information ends "Please see full Prescribing Information", but the link is springworkstx.com/ogsiveo-prescribing-information, which redirects to the nirogacestat (OGSIVEO) label PDF. The mirdametinib pipeline page links the GOMEKLI label correctly at /gomekli-prescribing-info.Source
  • 03

    The desmoid and NF1 pages' title tags still read "...(DeFi) Trial" and "NF1 Plexiform Neurofibroma Trial", the words search results show, although both medicines are now approved and the pages say so. A patient or caregiver searching the disease may read SpringWorks as running a study rather than offering support.

    Medium impactLow effort First result in 1 month Omnichannel Marketing Lead

    First action

    Draft new titles and descriptions for the two pages.

    How to measure it

    Disease-page search click-through

    Now
    –
    Target
    +20%
    By
    90 days

    Steps

    1. 1

      Draft titles

      Two pages plus /patients.

      Omnichannel Marketing Lead 1 day

    2. 2

      Add support links

      Product sites and CareConnections.

      Omnichannel Marketing Lead 1 day

    3. 3

      MLR review

      Titles, descriptions and links.

      Medical, Legal and Regulatory review 2 weeks

    4. 4

      Publish

      Update the CMS fields.

      Omnichannel Marketing Lead 1 hour

    5. 5

      Check snippets

      Search results after recrawl.

      Omnichannel Marketing Lead 2 weeks

    6. 6

      Measure

      Clicks and outbound clicks to support.

      Commercial Operations monthly

    First result
    1 month
    Cost
    $0
    Owner
    Omnichannel Marketing Lead

    Smallest test

    Change the desmoid page title this week.

    Why it works

    Rewrite the titles and descriptions as disease pages (for example "Desmoid Tumors: Information for Patients and Care Partners | SpringWorks"), and add clear links to the approved product sites and the springworkstxcares.com support programme for people already prescribed, alongside the advocacy links already there. Keep wording within the approved label and take it through MLR.

    Accurate titles match what people search for, and a link to support helps prescribed patients find help faster.

    Risks and how to handle them

    • Branded and unbranded content rules

      Keep the disease page unbranded in body copy if regulatory prefers, with links in a clearly labelled section.

    Evidence

    • Your websitespringworkstx.com disease pages: the desmoid page's title tag is "Desmoid Tumor / Fibromatosis (DeFi) Trial - SpringWorks Therapeutics" and the NF1 page's is "NF1 Plexiform Neurofibroma Trial - SpringWorks Therapeutics", though both pages now say the medicines are "approved in the U.S." Their outbound links go to desmoidtumors.com or nf1pn.com and advocacy groups; neither links to ogsiveo.com, gomekli.com or the springworkstxcares.com support site, which only the Our Medicines page lists.Source
    • HiringCompany description in every post: "SpringWorks Therapeutics, a healthcare company of Merck KGaA, Darmstadt, Germany, is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with rare tumors", which developed "the first and only FDA and EC approved medicine for adults with desmoid tumors and the first and only FDA and EC approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN)".Source
    • Your websiteDisease page facts: desmoid diagnosis "is typically made with a core-needle biopsy" and "it is helpful for an expert soft-tissue pathologist to confirm the desmoid tumor diagnosis"; surgery "has become less commonly recommended in recent treatment guidelines". NF1: "nearly 100,000 people are living with NF1 in the United States", "about 30-50%" develop plexiform neurofibromas, "most often diagnosed in the first two decades of life".Source
  • 04

    Since Merck KGaA completed the acquisition, SpringWorks is no longer a listed company, but the top menu still leads with "Press Releases" and "Events & Presentations" on investor-relations subdomains. Visitors now are clinicians, patients, advocates and candidates.

    Medium impactLow effort First result in 1 month Corporate Communications

    First action

    Rename the menu items and group the last ten releases.

    How to measure it

    News section visits

    Now
    –
    Target
    +30%
    By
    2 quarters

    Steps

    1. 1

      Map readers

      Who visits news now.

      Corporate Communications 1 week

    2. 2

      Restructure

      Three groups.

      Omnichannel Marketing Lead 1 week

    3. 3

      Summaries

      Plain-language versions of key releases.

      Corporate Communications 2 weeks

    4. 4

      Investor items

      Point to Merck KGaA.

      Corporate Communications 1 day

    5. 5

      Review

      Medical and legal sign-off.

      Medical, Legal and Regulatory review 2 weeks

    6. 6

      Measure

      Visits by source.

      Commercial Operations monthly

    First result
    1 month
    Cost
    Staff time only
    Owner
    Corporate Communications

    Smallest test

    Rename the two menu items.

    Why it works

    Rename the section to "News", group items by audience (medical data, patient community, company), add the long-term DeFi publication and the EU approvals as plain-language summaries, and retire investor-event listings or point them to Merck KGaA's investor pages.

    A news section built for current readers keeps the site useful after the acquisition and gives the field team links worth sharing.

    Risks and how to handle them

    • Group-level communication rules

      Agree the structure with Merck KGaA communications.

    Evidence

    • Your websitespringworkstx.com homepage: "SpringWorks Therapeutics, Inc. is a healthcare company of Merck KGaA, Darmstadt, Germany"; the top menu still carries the former public-company sections "Press Releases" and "Events & Presentations" on investor-relations subdomains. Recent news: long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO published in the Journal of Clinical Oncology; European Commission approval of OGSIVEO and conditional approval of EZMEKLY (mirdametinib). A German site is at de.springworkstx.com.Source
    • News coverageMerck KGaA, Darmstadt, Germany completed its acquisition of SpringWorks on July 1, 2025 (enterprise value about $3.4 billion), forming a rare tumor business.Source
  • 05

    ogsiveo.com's Patient Mentor Program page says the programme "is no longer being offered", but it is still in the sitemap with its registration text, so people may still land on a dead end from search.

    Medium impactLow effort First result in 1 month Patient Services Lead

    First action

    Decide redirect or replacement.

    How to measure it

    Old-page visitors reaching support

    Now
    –
    Target
    60%
    By
    60 days

    Steps

    1. 1

      Check traffic

      Visits to the page.

      Omnichannel Marketing Lead 1 day

    2. 2

      Decide

      Redirect or replace.

      Patient Services Lead (CareConnections) 1 week

    3. 3

      Review

      MLR.

      Medical, Legal and Regulatory review 2 weeks

    4. 4

      Update

      Redirect and sitemap.

      Omnichannel Marketing Lead 1 day

    5. 5

      Tell partners

      Advocacy groups linking to it.

      Patient Services Lead (CareConnections) 1 week

    6. 6

      Measure

      Support visits.

      Commercial Operations monthly

    First result
    1 month
    Cost
    $0
    Owner
    Patient Services Lead (CareConnections)

    Smallest test

    Remove the page from the sitemap.

    Why it works

    Either redirect the page to the patient support programme and the resource library, or, if peer connection still matters to prescribed patients, replace it with links to advocacy groups' peer programmes. Remove it from the sitemap.

    A clear next step keeps patients on the support path instead of leaving them at a closed form.

    Risks and how to handle them

    • Advocates link to the old page

      Ask them to update their links.

    Evidence

    • Your websiteBrand sites: ogsiveo.com offers a Spanish patient brochure, the OGSIVEO Digital Companion and a savings PDF; its Patient Mentor Program page says "the OGSIVEO Mentor Program is no longer being offered" but stays in the sitemap with its registration form text. gomekli.com has adult and children treatment pages, a find-a-doctor tool, and Spanish brochures and doctor discussion guides.Source
    • Your websiteogsiveo.com HCP site (sitemap checked October 23, 2026): sections for desmoid treatment, overview and data, dosing and management, patient support and access, practice resources, patient profiles, videos and Connect With Us; no page for payers, formulary decision-makers, pharmacists or GPOs. The Connect With Us form lists specialties "Oncology", "Surgery", "NP/RN/PA" and "Other". The access page describes SpringWorks CareConnections, Quick Start and Bridge programs, a commercial copay program, Field Access Managers and specialty pharmacy ordering.Source
  • 06

    The homepage is fine for real visitors, but across springworkstx.com Chrome users see a CLS of 0.17, above the "good" line. On pharma sites a common cause is a safety information tray or cookie banner that pushes content as it loads.

    Medium impactLow effort First result in 1 quarter Omnichannel Marketing Lead

    First action

    Run PageSpeed on the disease and pipeline pages.

    How to measure it

    Origin CLS p75

    Now
    –
    Target
    under 0.1
    By
    2 quarters

    Steps

    1. 1

      Test templates

      Disease, pipeline, medicines.

      Omnichannel Marketing Lead 1 day

    2. 2

      Find causes

      Tray, banner, videos.

      Web Developer 2 days

    3. 3

      Reserve space

      Fixed heights.

      Web Developer 1 week

    4. 4

      Image sizes

      Width and height set.

      Web Developer 2 days

    5. 5

      Re-test

      Lab and field.

      Omnichannel Marketing Lead 1 week

    6. 6

      Monitor

      Monthly CrUX.

      Omnichannel Marketing Lead monthly

    First result
    1 quarter
    Cost
    Developer time
    Owner
    Omnichannel Marketing Lead

    Smallest test

    Fix the template with the highest shift.

    Why it works

    Find the templates with the most movement (PageSpeed on the disease, pipeline and medicines pages), reserve space for the safety tray, banners and embedded videos, and set image sizes.

    Stable pages read better, especially long disease pages with safety text, and keep search signals healthy.

    Risks and how to handle them

    • Required safety tray behaviour

      Keep the tray visible; only fix how it loads.

    Evidence

    • Google PageSpeedspringworkstx.com: the homepage passes for real visitors (LCP 2.05 s, INP 94 ms, CLS 0.02), but across the whole site Chrome users see a CLS of 0.17 at the 75th percentile, above the 0.1 "good" line. Mobile lab score 54 (LCP 11.0 s, where the largest element is the homepage intro paragraph); desktop 69.Source
    • YouTubeThe SpringWorks YouTube channel has 12 videos, about 1.1 million views and 74 subscribers. The disease pages embed patient stories ("Watch Kevin's desmoid tumor story", "Watch Diane and Alex's NF1-PN story").Source

This quarter 9

The core plays for the next three months.

  • 07

    The payer role must "drive pull-through of GPO strategy" and "equip field teams with coordinated value messaging", and the West Regional Business Director must increase "access to the brand" with Market Access. Territory teams need to know, account by account, what coverage and support applies.

    High impactMedium effort First result in 1 quarter Associate Director

    First action

    Build the sheet for ten West accounts.

    How to measure it

    Covered accounts with first fill in 60 days

    Now
    –
    Target
    +20%
    By
    2 quarters

    Steps

    1. 1

      Define fields

      Coverage, affiliation, pharmacy, programmes.

      Associate Director, Payer & Access Marketing 1 week

    2. 2

      Data sources

      Access and channel data.

      Commercial Operations 2 weeks

    3. 3

      Pilot

      Ten West accounts.

      Regional Business Director, West 1 month

    4. 4

      Train

      TBMs and Field Access Managers.

      Associate Director, Payer & Access Marketing 2 weeks

    5. 5

      Scale

      All regions.

      Commercial Operations 1 quarter

    6. 6

      Measure

      Pull-through by account.

      Commercial Operations monthly

    First result
    1 quarter
    Cost
    Analyst time
    Owner
    Associate Director, Payer & Access Marketing

    Smallest test

    Pilot the sheet in one territory.

    Why it works

    Give each Territory Business Manager and Field Access Manager a monthly sheet per key account: coverage status, GPO or IDN affiliation, specialty pharmacy, Quick Start and Bridge availability, and the approved resource to use. Track which accounts move from restricted to covered.

    Pull-through fails when field teams do not know what was won; account-level detail turns contracts into prescriptions written and filled.

    Risks and how to handle them

    • Compliance on patient support

      Keep field use of support programmes within approved rules.

    Evidence

    • HiringAssociate Director, Payer & Access Marketing - US Rare Tumors (OGSIVEO) (Boston hybrid, posted September 14, 2026): will "shape and execute the OGSIVEO value proposition across US market access channels" for "payers, population-based decision-makers, pharmacists, GPOs, and external thought leaders"; will "Head the strategy and execution of non-personal promotion initiatives for market access audiences", drive "pull-through of GPO strategy", build "measurement frameworks", move work through MLR review, and "equip field teams with coordinated value messaging in a more competitive market"; external groups named include "PBMs", "COA, NCODA, ASCO, NCCN".Source
    • HiringRegional Business Director - West Region (OGSIVEO) (field, posted September 22, 2026): leads the region's Territory Business Managers, builds "regional business strategies to increase access to the brand" with Market Access, keeps relationships "with key physician practices, hospitals/clinics, and patient advocacy organizations", and must "Communicate competitive market intelligence to brand teams".Source
    • Your websiteogsiveo.com HCP site (sitemap checked October 23, 2026): sections for desmoid treatment, overview and data, dosing and management, patient support and access, practice resources, patient profiles, videos and Connect With Us; no page for payers, formulary decision-makers, pharmacists or GPOs. The Connect With Us form lists specialties "Oncology", "Surgery", "NP/RN/PA" and "Other". The access page describes SpringWorks CareConnections, Quick Start and Bridge programs, a commercial copay program, Field Access Managers and specialty pharmacy ordering.Source
  • 08

    Three GOMEKLI territory roles opened in the last month, asking for pediatric and adult neurology experience and relationships with major cancer centers. New territories ramp faster when the map of NF care is ready on day one.

    High impactMedium effort First result in 1 quarter GOMEKLI Brand Lead

    First action

    Build the Phoenix account map.

    How to measure it

    Days to tenth active account

    Now
    –
    Target
    -30%
    By
    2 quarters

    Steps

    1. 1

      Map NF care

      Clinics, neurology, oncology, centers.

      Commercial Operations 2 weeks

    2. 2

      Resource kit

      Approved materials per audience.

      GOMEKLI Brand Lead 2 weeks

    3. 3

      Find-a-doctor check

      Listings per territory.

      Omnichannel Marketing Lead 1 week

    4. 4

      Onboard

      Kit in first-week training.

      Field Enablement Training 1 week

    5. 5

      Advocacy contacts

      Local chapters.

      Regional Business Director, West 1 month

    6. 6

      Review

      Ramp after 90 days.

      Commercial Operations quarterly

    First result
    1 quarter
    Cost
    Staff time only
    Owner
    GOMEKLI Brand Lead

    Smallest test

    Map one territory before the hire starts.

    Build the prospect list. The list compiled from public sources, verified, deduplicated and delivered to your CRM. Usually live within days.

    Book a working session

    Why it works

    For each territory, build a list of NF clinics (starting with the clinic network of the Children's Tumor Foundation, which the NF1 page already links), pediatric and adult neurology and oncology practices, and major cancer centers, with the approved resources for each audience and the gomekli.com find-a-doctor listings to keep current.

    Rare disease patients are concentrated in a few centers; knowing them early shortens the ramp of each new hire.

    Risks and how to handle them

    • Outdated clinic lists

      Refresh quarterly.

    Evidence

    • HiringTerritory Business Manager (GOMEKLI) openings in New Orleans (posted September 30, 2026), Phoenix and Seattle (both posted October 19, 2026): relationships with HCPs, practice managers and "major cancer centers", "Neurology experience - pediatric and adult experience preferred", "Strong expertise in reimbursement and managed care knowledge", and "embracing the digital platforms/omnichannel strategies".Source
    • Your websitespringworkstx.com disease pages: the desmoid page's title tag is "Desmoid Tumor / Fibromatosis (DeFi) Trial - SpringWorks Therapeutics" and the NF1 page's is "NF1 Plexiform Neurofibroma Trial - SpringWorks Therapeutics", though both pages now say the medicines are "approved in the U.S." Their outbound links go to desmoidtumors.com or nf1pn.com and advocacy groups; neither links to ogsiveo.com, gomekli.com or the springworkstxcares.com support site, which only the Our Medicines page lists.Source
    • Your websiteBrand sites: ogsiveo.com offers a Spanish patient brochure, the OGSIVEO Digital Companion and a savings PDF; its Patient Mentor Program page says "the OGSIVEO Mentor Program is no longer being offered" but stays in the sitemap with its registration form text. gomekli.com has adult and children treatment pages, a find-a-doctor tool, and Spanish brochures and doctor discussion guides.Source
  • 09

    SpringWorks says GOMEKLI is the first and only FDA and EC approved medicine for both adults and children with NF1-PN, and its page notes another MEK inhibitor is approved for children. NF1-PN is most often diagnosed before age 20, so many adults are followed by doctors who see few NF1 patients.

    High impactMedium effort First result in 2 quarters GOMEKLI Brand Lead

    First action

    Size the adult NF1 prescriber universe.

    How to measure it

    Adult prescribers

    Now
    –
    Target
    +25%
    By
    3 quarters

    Steps

    1. 1

      Size universe

      Adult NF1 physicians.

      Market Research Lead 1 month

    2. 2

      Content

      On-label adult resources.

      GOMEKLI Brand Lead 1 month

    3. 3

      MLR

      All materials.

      Medical, Legal and Regulatory review 1 month

    4. 4

      Channels

      Email, journals, congress.

      Omnichannel Marketing Lead 1 quarter

    5. 5

      Field follow-up

      TBMs in priority accounts.

      Territory Business Manager (GOMEKLI) ongoing

    6. 6

      Measure

      Engagement and prescribers.

      Commercial Operations monthly

    First result
    2 quarters
    Cost
    Media and agency budget
    Owner
    GOMEKLI Brand Lead

    Smallest test

    Send one adult-focused HCP email.

    Why it works

    Run HCP education and non-personal promotion for adult neurologists, oncologists and internists in NF transition and adult NF clinics, within the label: the adult data, dosing and monitoring guide, and how to reach patient support. Measure HCP engagement and new adult prescribers.

    The adult indication is the clearest point of difference, and adult care is spread across more doctors than pediatric care.

    Risks and how to handle them

    • Off-label discussion

      Keep all promotion within the approved indication.

    Evidence

    • HiringCompany description in every post: "SpringWorks Therapeutics, a healthcare company of Merck KGaA, Darmstadt, Germany, is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with rare tumors", which developed "the first and only FDA and EC approved medicine for adults with desmoid tumors and the first and only FDA and EC approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN)".Source
    • News coverageThe FDA accepted Immunome's New Drug Application for varegacestat, an investigational gamma secretase inhibitor for adults with desmoid tumors, with an action date of April 28, 2027. SpringWorks' NF1 page notes that the FDA "approved another drug from the MEK inhibitor class for the treatment of children with NF1-PN".Source
    • Your websiteDisease page facts: desmoid diagnosis "is typically made with a core-needle biopsy" and "it is helpful for an expert soft-tissue pathologist to confirm the desmoid tumor diagnosis"; surgery "has become less commonly recommended in recent treatment guidelines". NF1: "nearly 100,000 people are living with NF1 in the United States", "about 30-50%" develop plexiform neurofibromas, "most often diagnosed in the first two decades of life".Source
    • HiringTerritory Business Manager (GOMEKLI) openings in New Orleans (posted September 30, 2026), Phoenix and Seattle (both posted October 19, 2026): relationships with HCPs, practice managers and "major cancer centers", "Neurology experience - pediatric and adult experience preferred", "Strong expertise in reimbursement and managed care knowledge", and "embracing the digital platforms/omnichannel strategies".Source
  • 10

    The payer role names NCODA among the external groups to work with. Oral oncolytics are often dispensed by practices' own pharmacies, where pharmacists handle access, first fills and side-effect follow-up.

    Medium impactMedium effort First result in 1 quarter Associate Director

    First action

    List practices with medically integrated pharmacies in the West.

    How to measure it

    Days from prescription to first fill

    Now
    –
    Target
    -20%
    By
    2 quarters

    Steps

    1. 1

      List practices

      In-house pharmacies.

      Commercial Operations 2 weeks

    2. 2

      Resources

      Approved pharmacist kit.

      Associate Director, Payer & Access Marketing 1 month

    3. 3

      MLR

      Review.

      Medical, Legal and Regulatory review 1 month

    4. 4

      Meetings

      Pharmacist events.

      Associate Director, Payer & Access Marketing quarterly

    5. 5

      Contact route

      Access questions.

      Patient Services Lead (CareConnections) 2 weeks

    6. 6

      Measure

      Time to first fill.

      Commercial Operations monthly

    First result
    1 quarter
    Cost
    Event budget
    Owner
    Associate Director, Payer & Access Marketing

    Smallest test

    Meet one practice pharmacy team.

    Why it works

    Prepare approved pharmacist resources (dosing, monitoring and management guides, ordering and support programmes), exhibit and present at pharmacist meetings, and offer in-practice pharmacy teams a direct contact for access questions.

    Pharmacists influence how quickly a prescription becomes a first dose and whether patients stay on therapy.

    Risks and how to handle them

    • Small audience

      Focus on practices that treat sarcoma and NF.

    Evidence

    • HiringAssociate Director, Payer & Access Marketing - US Rare Tumors (OGSIVEO) (Boston hybrid, posted September 14, 2026): will "shape and execute the OGSIVEO value proposition across US market access channels" for "payers, population-based decision-makers, pharmacists, GPOs, and external thought leaders"; will "Head the strategy and execution of non-personal promotion initiatives for market access audiences", drive "pull-through of GPO strategy", build "measurement frameworks", move work through MLR review, and "equip field teams with coordinated value messaging in a more competitive market"; external groups named include "PBMs", "COA, NCODA, ASCO, NCCN".Source
    • Your websiteogsiveo.com HCP site (sitemap checked October 23, 2026): sections for desmoid treatment, overview and data, dosing and management, patient support and access, practice resources, patient profiles, videos and Connect With Us; no page for payers, formulary decision-makers, pharmacists or GPOs. The Connect With Us form lists specialties "Oncology", "Surgery", "NP/RN/PA" and "Other". The access page describes SpringWorks CareConnections, Quick Start and Bridge programs, a commercial copay program, Field Access Managers and specialty pharmacy ordering.Source
  • 11

    Long-term efficacy and safety data from the Phase 3 DeFi trial were published in the Journal of Clinical Oncology, and the West MSL presents "outcomes-based product presentations to managed-care customers". A competing medicine is under FDA review with an April 2027 action date.

    High impactMedium effort First result in 1 quarter Medical Affairs Lead

    First action

    Draft the summary outline with Medical Affairs.

    How to measure it

    Plans briefed

    Now
    –
    Target
    30
    By
    2 quarters

    Steps

    1. 1

      Outline

      Key results for payers.

      Medical Affairs Lead 2 weeks

    2. 2

      Review

      Medical and legal.

      Medical, Legal and Regulatory review 1 month

    3. 3

      Dossier update

      Add the publication.

      Associate Director, Payer & Access Marketing 1 month

    4. 4

      MSL training

      Managed-care presentations.

      Medical Affairs Lead 2 weeks

    5. 5

      Deliver

      Plan meetings.

      Medical Science Liaison, West ongoing

    6. 6

      Track

      Requests and decisions.

      Associate Director, Payer & Access Marketing monthly

    First result
    1 quarter
    Cost
    Medical writing
    Owner
    Medical Affairs Lead

    Smallest test

    Brief three plans.

    Why it works

    Prepare a medical summary of the publication for payer and P&T audiences (through Medical Affairs, within what the data and rules allow), add it to dossier updates and managed-care presentations, and track which plans request it.

    Payers decide on evidence; having the latest data in their format before a second option arrives keeps the conversation on facts.

    Risks and how to handle them

    • Promotional versus scientific use

      Keep medical and commercial roles separate as required.

    Evidence

    • Your websitespringworkstx.com homepage: "SpringWorks Therapeutics, Inc. is a healthcare company of Merck KGaA, Darmstadt, Germany"; the top menu still carries the former public-company sections "Press Releases" and "Events & Presentations" on investor-relations subdomains. Recent news: long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO published in the Journal of Clinical Oncology; European Commission approval of OGSIVEO and conditional approval of EZMEKLY (mirdametinib). A German site is at de.springworkstx.com.Source
    • HiringMedical Science Liaison / Senior MSL - West Region (WA, OR, CA, NV, AZ, HI, AK; board updated October 15, 2026): builds scientific relationships with KOLs "in academic centers and community practices", staffs "disease state booths" at congresses, and serves "as a Medical Affairs lead for disease state and outcomes-based product presentations to managed-care customers".Source
    • News coverageThe FDA accepted Immunome's New Drug Application for varegacestat, an investigational gamma secretase inhibitor for adults with desmoid tumors, with an action date of April 28, 2027. SpringWorks' NF1 page notes that the FDA "approved another drug from the MEK inhibitor class for the treatment of children with NF1-PN".Source
    • HiringAssociate Director, Payer & Access Marketing - US Rare Tumors (OGSIVEO) (Boston hybrid, posted September 14, 2026): will "shape and execute the OGSIVEO value proposition across US market access channels" for "payers, population-based decision-makers, pharmacists, GPOs, and external thought leaders"; will "Head the strategy and execution of non-personal promotion initiatives for market access audiences", drive "pull-through of GPO strategy", build "measurement frameworks", move work through MLR review, and "equip field teams with coordinated value messaging in a more competitive market"; external groups named include "PBMs", "COA, NCODA, ASCO, NCCN".Source
  • 12

    Both brand sites already offer Spanish patient brochures and GOMEKLI has Spanish doctor discussion guides, but the support pages and the corporate disease pages are English only.

    High impactMedium effort First result in 1 quarter Patient Services Lead

    First action

    Check whether CareConnections offers Spanish today.

    How to measure it

    Spanish enrolments

    Now
    –
    Target
    +30%
    By
    2 quarters

    Steps

    1. 1

      Check current service

      Spanish phone and staff.

      Patient Services Lead (CareConnections) 1 week

    2. 2

      Write pages

      Spanish support pages.

      Omnichannel Marketing Lead 1 month

    3. 3

      Review

      MLR in both languages.

      Medical, Legal and Regulatory review 1 month

    4. 4

      Link

      From Spanish brochures.

      Omnichannel Marketing Lead 1 week

    5. 5

      Train

      Field Access Managers.

      Patient Services Lead (CareConnections) 2 weeks

    6. 6

      Measure

      Enrolment by language.

      Commercial Operations monthly

    First result
    1 quarter
    Cost
    Translation budget
    Owner
    Patient Services Lead (CareConnections)

    Smallest test

    Add a Spanish line to the support page.

    Why it works

    Add a Spanish landing page for patient support on each brand site and a Spanish-language phone option at CareConnections, linked from the Spanish brochures. Measure enrolment by language.

    Spanish-speaking patients who are already prescribed get support faster when they can find it in their language.

    Risks and how to handle them

    • Translation accuracy

      Use medical translators and review.

    Evidence

    • Your websiteBrand sites: ogsiveo.com offers a Spanish patient brochure, the OGSIVEO Digital Companion and a savings PDF; its Patient Mentor Program page says "the OGSIVEO Mentor Program is no longer being offered" but stays in the sitemap with its registration form text. gomekli.com has adult and children treatment pages, a find-a-doctor tool, and Spanish brochures and doctor discussion guides.Source
    • Your websiteogsiveo.com HCP site (sitemap checked October 23, 2026): sections for desmoid treatment, overview and data, dosing and management, patient support and access, practice resources, patient profiles, videos and Connect With Us; no page for payers, formulary decision-makers, pharmacists or GPOs. The Connect With Us form lists specialties "Oncology", "Surgery", "NP/RN/PA" and "Other". The access page describes SpringWorks CareConnections, Quick Start and Bridge programs, a commercial copay program, Field Access Managers and specialty pharmacy ordering.Source
  • 13

    SpringWorks' own page says diagnosis is made by core-needle biopsy and that an expert soft-tissue pathologist's confirmation helps. A slower or missed diagnosis delays every later decision.

    Medium impactMedium effort First result in 2 quarters Medical Affairs Lead

    First action

    Interview three pathologists about referral today.

    How to measure it

    Pathologists engaged

    Now
    –
    Target
    1,000
    By
    3 quarters

    Steps

    1. 1

      Interviews

      Pathologists and radiologists.

      Medical Affairs Lead 1 month

    2. 2

      Content

      Unbranded education.

      Medical Affairs Lead 2 months

    3. 3

      Review

      Medical and legal.

      Medical, Legal and Regulatory review 1 month

    4. 4

      Congresses

      Pathology meetings.

      Medical Science Liaison, West annual

    5. 5

      Journals

      Education pieces.

      Medical Affairs Lead 1 quarter

    6. 6

      Measure

      Reach and feedback.

      Medical Affairs Lead quarterly

    First result
    2 quarters
    Cost
    Medical education budget
    Owner
    Medical Affairs Lead

    Smallest test

    Run one webinar for pathologists.

    Why it works

    Create unbranded disease-state education for general pathologists and radiologists (diagnosis, referral to sarcoma centers) through Medical Affairs, at their congresses and in journals, with no product promotion.

    Faster, accurate diagnosis and referral help patients reach specialist care; it also builds Medical Affairs relationships beyond oncology.

    Risks and how to handle them

    • Perceived as promotion

      Keep it unbranded and medical-led.

    Evidence

    • Your websiteDisease page facts: desmoid diagnosis "is typically made with a core-needle biopsy" and "it is helpful for an expert soft-tissue pathologist to confirm the desmoid tumor diagnosis"; surgery "has become less commonly recommended in recent treatment guidelines". NF1: "nearly 100,000 people are living with NF1 in the United States", "about 30-50%" develop plexiform neurofibromas, "most often diagnosed in the first two decades of life".Source
    • HiringMedical Science Liaison / Senior MSL - West Region (WA, OR, CA, NV, AZ, HI, AK; board updated October 15, 2026): builds scientific relationships with KOLs "in academic centers and community practices", staffs "disease state booths" at congresses, and serves "as a Medical Affairs lead for disease state and outcomes-based product presentations to managed-care customers".Source
  • 14

    The YouTube channel has about 1.1 million views across 12 videos but only 74 subscribers, so people watch the stories (often embedded or promoted) without staying connected.

    Medium impactLow effort First result in 1 quarter Omnichannel Marketing Lead

    First action

    Add captions and chapters to the two disease videos.

    How to measure it

    Channel subscribers

    Now
    –
    Target
    1,000
    By
    2 quarters

    Steps

    1. 1

      Review videos

      Consent and MLR status.

      Medical, Legal and Regulatory review 2 weeks

    2. 2

      Captions

      English and Spanish.

      Omnichannel Marketing Lead 2 weeks

    3. 3

      Playlists

      Per disease.

      Omnichannel Marketing Lead 1 day

    4. 4

      Links

      To support sites.

      Omnichannel Marketing Lead 1 day

    5. 5

      New stories

      With advocates.

      Patient Services Lead (CareConnections) 1 quarter

    6. 6

      Measure

      Watch time and clicks.

      Omnichannel Marketing Lead monthly

    First result
    1 quarter
    Cost
    Production budget
    Owner
    Omnichannel Marketing Lead

    Smallest test

    Caption one video.

    Why it works

    With consent and MLR review, add chapters, captions and Spanish subtitles to the patient stories, group them in a playlist per disease, link each to the support site, and add a subscribe prompt. Add new stories with advocacy partners.

    Patient stories help people feel less alone; making them easy to find and follow multiplies that.

    Risks and how to handle them

    • Patient privacy

      Renew consents and follow rules on patient testimonials.

    Evidence

    • YouTubeThe SpringWorks YouTube channel has 12 videos, about 1.1 million views and 74 subscribers. The disease pages embed patient stories ("Watch Kevin's desmoid tumor story", "Watch Diane and Alex's NF1-PN story").Source
    • Your websiteBrand sites: ogsiveo.com offers a Spanish patient brochure, the OGSIVEO Digital Companion and a savings PDF; its Patient Mentor Program page says "the OGSIVEO Mentor Program is no longer being offered" but stays in the sitemap with its registration form text. gomekli.com has adult and children treatment pages, a find-a-doctor tool, and Spanish brochures and doctor discussion guides.Source
  • 15

    The disease pages link the Desmoid Tumor Research Foundation, the Children's Tumor Foundation, NF Network and others, and the regional director is asked to work with "patient advocacy organizations".

    Medium impactMedium effort First result in 2 quarters Regional Business Director

    First action

    Ask two groups what education they need.

    How to measure it

    Attendees at partner events

    Now
    –
    Target
    1,500
    By
    3 quarters

    Steps

    1. 1

      Ask groups

      Needs and calendar.

      Regional Business Director, West 1 month

    2. 2

      Grants process

      Independent and documented.

      Medical Grants 1 month

    3. 3

      Events

      Regional education days.

      Advocacy Relations quarterly

    4. 4

      Materials

      Unbranded where required.

      Medical, Legal and Regulatory review 1 month

    5. 5

      Feedback

      From families.

      Advocacy Relations quarterly

    6. 6

      Report

      Transparency disclosures.

      Compliance annual

    First result
    2 quarters
    Cost
    Grants budget
    Owner
    Regional Business Director, West

    Smallest test

    Fund one education day.

    Why it works

    Offer transparent, compliant sponsorship of patient and caregiver education days (disease, living with treatment, support programmes) organised by the groups, with SpringWorks speakers only where rules allow.

    Patients trust advocates; supporting their education reaches families without promotional messages.

    Risks and how to handle them

    • Independence of groups

      Use arm's-length grants and disclose them.

    Evidence

    • Your websitespringworkstx.com disease pages: the desmoid page's title tag is "Desmoid Tumor / Fibromatosis (DeFi) Trial - SpringWorks Therapeutics" and the NF1 page's is "NF1 Plexiform Neurofibroma Trial - SpringWorks Therapeutics", though both pages now say the medicines are "approved in the U.S." Their outbound links go to desmoidtumors.com or nf1pn.com and advocacy groups; neither links to ogsiveo.com, gomekli.com or the springworkstxcares.com support site, which only the Our Medicines page lists.Source
    • HiringRegional Business Director - West Region (OGSIVEO) (field, posted September 22, 2026): leads the region's Territory Business Managers, builds "regional business strategies to increase access to the brand" with Market Access, keeps relationships "with key physician practices, hospitals/clinics, and patient advocacy organizations", and must "Communicate competitive market intelligence to brand teams".Source

Big bets 3

Larger plays that can change the trajectory.

  • 16

    The payer post speaks of "a more competitive market", and an investigational gamma secretase inhibitor has an FDA action date of April 28, 2027. Payers often revisit coverage when a second option is approved.

    High impactHigh effort First result in 3 quarters Associate Director

    First action

    Book a payer advisory board.

    How to measure it

    Covered lives maintained

    Now
    –
    Target
    95%
    By
    4 quarters

    Steps

    1. 1

      Payer research

      Advisory boards.

      Market Research Lead 1 quarter

    2. 2

      Value story

      Refresh within label.

      Associate Director, Payer & Access Marketing 1 quarter

    3. 3

      Contracting plan

      GPO and PBM options.

      Market Access Director 1 quarter

    4. 4

      Field training

      Approved messaging.

      Associate Director, Payer & Access Marketing 1 month

    5. 5

      Monitor

      Policy changes.

      Associate Director, Payer & Access Marketing monthly

    6. 6

      Review

      After the FDA decision.

      OGSIVEO Brand Lead quarterly

    First result
    3 quarters
    Cost
    Research budget
    Owner
    Associate Director, Payer & Access Marketing

    Smallest test

    Run one payer advisory board.

    Why it works

    Run payer advisory research now, refresh the value story within the label (long-term data, real-world support outcomes, total cost of care), plan contracting options with GPOs and PBMs, and brief the field on fair, approved competitive messaging.

    Access positions set before a competitor arrives are easier to keep than to win back.

    Risks and how to handle them

    • Unknown competitor label

      Prepare scenarios, not claims about the other product.

    Evidence

    • HiringAssociate Director, Payer & Access Marketing - US Rare Tumors (OGSIVEO) (Boston hybrid, posted September 14, 2026): will "shape and execute the OGSIVEO value proposition across US market access channels" for "payers, population-based decision-makers, pharmacists, GPOs, and external thought leaders"; will "Head the strategy and execution of non-personal promotion initiatives for market access audiences", drive "pull-through of GPO strategy", build "measurement frameworks", move work through MLR review, and "equip field teams with coordinated value messaging in a more competitive market"; external groups named include "PBMs", "COA, NCODA, ASCO, NCCN".Source
    • News coverageThe FDA accepted Immunome's New Drug Application for varegacestat, an investigational gamma secretase inhibitor for adults with desmoid tumors, with an action date of April 28, 2027. SpringWorks' NF1 page notes that the FDA "approved another drug from the MEK inhibitor class for the treatment of children with NF1-PN".Source
    • Your websitespringworkstx.com homepage: "SpringWorks Therapeutics, Inc. is a healthcare company of Merck KGaA, Darmstadt, Germany"; the top menu still carries the former public-company sections "Press Releases" and "Events & Presentations" on investor-relations subdomains. Recent news: long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO published in the Journal of Clinical Oncology; European Commission approval of OGSIVEO and conditional approval of EZMEKLY (mirdametinib). A German site is at de.springworkstx.com.Source
    • HiringRegional Business Director - West Region (OGSIVEO) (field, posted September 22, 2026): leads the region's Territory Business Managers, builds "regional business strategies to increase access to the brand" with Market Access, keeps relationships "with key physician practices, hospitals/clinics, and patient advocacy organizations", and must "Communicate competitive market intelligence to brand teams".Source
  • 17

    Desmoid tumors and NF1-PN are treated at many of the same major cancer centers, and the Merck KGaA acquisition formed a rare tumor business. Today HCPs move between springworkstx.com, ogsiveo.com/hcp and gomekli.com/hcp for information, resources and contacts.

    Medium impactHigh effort First result in 4 quarters Omnichannel Marketing Lead

    First action

    Map what HCPs search for across the three sites.

    How to measure it

    Opted-in HCPs

    Now
    –
    Target
    +50%
    By
    4 quarters

    Steps

    1. 1

      Map journeys

      Across three sites.

      Omnichannel Marketing Lead 1 month

    2. 2

      Design hub

      Shared navigation.

      Omnichannel Marketing Lead 1 quarter

    3. 3

      Review

      MLR for structure.

      Medical, Legal and Regulatory review 1 month

    4. 4

      Build

      Hub and sign-up.

      Web Developer 1 quarter

    5. 5

      Launch

      Email and field.

      Omnichannel Marketing Lead 1 month

    6. 6

      Measure

      Sign-ups and visits.

      Commercial Operations monthly

    First result
    4 quarters
    Cost
    Build budget
    Owner
    Omnichannel Marketing Lead

    Smallest test

    Add cross-links between the two HCP sites.

    Why it works

    Build a shared HCP hub that links both brand HCP sites, medical information requests, support programmes, the payer section and congress materials, with one sign-up for updates by product. Keep each brand's content and safety information separate.

    Busy specialists use one source; one sign-up grows the reachable audience for both brands.

    Risks and how to handle them

    • Group brand rules

      Align with Merck KGaA digital standards.

    Evidence

    • Your websiteogsiveo.com HCP site (sitemap checked October 23, 2026): sections for desmoid treatment, overview and data, dosing and management, patient support and access, practice resources, patient profiles, videos and Connect With Us; no page for payers, formulary decision-makers, pharmacists or GPOs. The Connect With Us form lists specialties "Oncology", "Surgery", "NP/RN/PA" and "Other". The access page describes SpringWorks CareConnections, Quick Start and Bridge programs, a commercial copay program, Field Access Managers and specialty pharmacy ordering.Source
    • News coverageMerck KGaA, Darmstadt, Germany completed its acquisition of SpringWorks on July 1, 2025 (enterprise value about $3.4 billion), forming a rare tumor business.Source
    • Your websiteBrand sites: ogsiveo.com offers a Spanish patient brochure, the OGSIVEO Digital Companion and a savings PDF; its Patient Mentor Program page says "the OGSIVEO Mentor Program is no longer being offered" but stays in the sitemap with its registration form text. gomekli.com has adult and children treatment pages, a find-a-doctor tool, and Spanish brochures and doctor discussion guides.Source
    • HiringTerritory Business Manager (GOMEKLI) openings in New Orleans (posted September 30, 2026), Phoenix and Seattle (both posted October 19, 2026): relationships with HCPs, practice managers and "major cancer centers", "Neurology experience - pediatric and adult experience preferred", "Strong expertise in reimbursement and managed care knowledge", and "embracing the digital platforms/omnichannel strategies".Source
  • 18

    CareConnections offers Quick Start, Bridge, copay help, Field Access Managers and the OGSIVEO Digital Companion. Showing what these do (time to first dose, persistence, satisfaction) helps payers, prescribers and the programme team.

    High impactHigh effort First result in 4 quarters Patient Services Lead

    First action

    List the measures CareConnections already records.

    How to measure it

    Median days to first dose

    Now
    –
    Target
    -25%
    By
    4 quarters

    Steps

    1. 1

      Define measures

      Consented and aggregated.

      Patient Services Lead (CareConnections) 1 month

    2. 2

      Privacy review

      Data use and consent.

      Privacy Office 1 month

    3. 3

      Baseline

      Current results.

      Commercial Operations 1 month

    4. 4

      Improve

      First 90 days.

      Patient Services Lead (CareConnections) 2 quarters

    5. 5

      Report

      Quarterly.

      Patient Services Lead (CareConnections) quarterly

    6. 6

      Share

      With payers and field.

      Associate Director, Payer & Access Marketing quarterly

    First result
    4 quarters
    Cost
    Analyst time
    Owner
    Patient Services Lead (CareConnections)

    Smallest test

    Measure time to first dose for last quarter.

    Why it works

    Define consented, privacy-safe measures for the support programmes, report them quarterly in aggregate, and use the findings to improve the first 90 days on therapy (for example, earlier side-effect check-ins as described in the approved management guides).

    Support that is measured gets better and becomes part of the value story.

    Risks and how to handle them

    • Patient privacy

      Report only aggregated, consented data.

    Evidence

    • Your websiteogsiveo.com HCP site (sitemap checked October 23, 2026): sections for desmoid treatment, overview and data, dosing and management, patient support and access, practice resources, patient profiles, videos and Connect With Us; no page for payers, formulary decision-makers, pharmacists or GPOs. The Connect With Us form lists specialties "Oncology", "Surgery", "NP/RN/PA" and "Other". The access page describes SpringWorks CareConnections, Quick Start and Bridge programs, a commercial copay program, Field Access Managers and specialty pharmacy ordering.Source
    • Your websiteBrand sites: ogsiveo.com offers a Spanish patient brochure, the OGSIVEO Digital Companion and a savings PDF; its Patient Mentor Program page says "the OGSIVEO Mentor Program is no longer being offered" but stays in the sitemap with its registration form text. gomekli.com has adult and children treatment pages, a find-a-doctor tool, and Spanish brochures and doctor discussion guides.Source
    • HiringAssociate Director, Payer & Access Marketing - US Rare Tumors (OGSIVEO) (Boston hybrid, posted September 14, 2026): will "shape and execute the OGSIVEO value proposition across US market access channels" for "payers, population-based decision-makers, pharmacists, GPOs, and external thought leaders"; will "Head the strategy and execution of non-personal promotion initiatives for market access audiences", drive "pull-through of GPO strategy", build "measurement frameworks", move work through MLR review, and "equip field teams with coordinated value messaging in a more competitive market"; external groups named include "PBMs", "COA, NCODA, ASCO, NCCN".Source

Wildcards 3

Unexpected experiments, each with a cheap way to test it.

  • 19

    gomekli.com offers a find-a-doctor tool, and new territories in New Orleans, Phoenix and Seattle are about to build relationships with NF clinics.

    Medium impactLow effort First result in 1 quarter Omnichannel Marketing Lead

    First action

    Export searches with no results.

    How to measure it

    Searches with a result within 100 miles

    Now
    –
    Target
    90%
    By
    2 quarters

    Steps

    1. 1

      Export data

      Empty searches.

      Omnichannel Marketing Lead 1 week

    2. 2

      Listing process

      Consent from clinics.

      Compliance 1 month

    3. 3

      Field reports

      New clinics.

      Territory Business Manager (GOMEKLI) ongoing

    4. 4

      Update tool

      Distance results.

      Web Developer 1 month

    5. 5

      Review

      Quarterly.

      Omnichannel Marketing Lead quarterly

    6. 6

      Measure

      Result rate.

      Omnichannel Marketing Lead monthly

    First result
    1 quarter
    Cost
    Staff time only
    Owner
    Omnichannel Marketing Lead

    Smallest test

    Fix the top five empty searches.

    Why it works

    Give TBMs a simple way to report clinics that agree to be listed, add NF clinics and adult NF specialists, and show results by distance. Track searches with no result to find gaps.

    Families searching for an NF specialist need a nearby answer; empty searches show where care is thin.

    Risks and how to handle them

    • Listing rules

      List only clinicians who agree.

    Evidence

    • Your websiteBrand sites: ogsiveo.com offers a Spanish patient brochure, the OGSIVEO Digital Companion and a savings PDF; its Patient Mentor Program page says "the OGSIVEO Mentor Program is no longer being offered" but stays in the sitemap with its registration form text. gomekli.com has adult and children treatment pages, a find-a-doctor tool, and Spanish brochures and doctor discussion guides.Source
    • HiringTerritory Business Manager (GOMEKLI) openings in New Orleans (posted September 30, 2026), Phoenix and Seattle (both posted October 19, 2026): relationships with HCPs, practice managers and "major cancer centers", "Neurology experience - pediatric and adult experience preferred", "Strong expertise in reimbursement and managed care knowledge", and "embracing the digital platforms/omnichannel strategies".Source
  • 20

    OGSIVEO is approved and EZMEKLY conditionally approved in the EU, and the corporate site offers only US and German versions.

    Medium impactLow effort First result in 1 quarter Corporate Communications

    First action

    List the EU countries with local contacts.

    How to measure it

    EU visits reaching local pages

    Now
    –
    Target
    70%
    By
    2 quarters

    Steps

    1. 1

      List countries

      With affiliates.

      Corporate Communications 2 weeks

    2. 2

      Selector

      Country routing.

      Web Developer 1 month

    3. 3

      Content

      SmPC and contacts.

      Medical Affairs Lead 1 month

    4. 4

      Review

      Local regulatory.

      Medical, Legal and Regulatory review 1 month

    5. 5

      Launch

      Corporate site.

      Omnichannel Marketing Lead 1 week

    6. 6

      Measure

      Routing success.

      Omnichannel Marketing Lead monthly

    First result
    1 quarter
    Cost
    Developer time
    Owner
    Corporate Communications

    Smallest test

    Add a link to the EU product information page.

    Why it works

    Add a country selector that sends EU clinicians to the right SmPC, medical information contact and local Merck KGaA affiliate, without promotional content where it is not allowed.

    Clinicians outside the US then reach the right label and contact instead of US pages.

    Risks and how to handle them

    • Country rules differ

      Keep EU pages informational and locally reviewed.

    Evidence

    • Your websitespringworkstx.com homepage: "SpringWorks Therapeutics, Inc. is a healthcare company of Merck KGaA, Darmstadt, Germany"; the top menu still carries the former public-company sections "Press Releases" and "Events & Presentations" on investor-relations subdomains. Recent news: long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO published in the Journal of Clinical Oncology; European Commission approval of OGSIVEO and conditional approval of EZMEKLY (mirdametinib). A German site is at de.springworkstx.com.Source
    • News coverageMerck KGaA, Darmstadt, Germany completed its acquisition of SpringWorks on July 1, 2025 (enterprise value about $3.4 billion), forming a rare tumor business.Source
  • 21

    The OGSIVEO Digital Companion appears on both the patient and HCP sites. Digital tools help only if prescribed patients start and keep using them.

    Medium impactLow effort First result in 1 quarter OGSIVEO Brand Lead

    First action

    Add a source tag to each Digital Companion link.

    How to measure it

    Active users among new patients

    Now
    –
    Target
    40%
    By
    2 quarters

    Steps

    1. 1

      Source tags

      Each link.

      Omnichannel Marketing Lead 1 week

    2. 2

      QR code

      Getting-started materials.

      OGSIVEO Brand Lead 1 month

    3. 3

      Review

      MLR.

      Medical, Legal and Regulatory review 1 month

    4. 4

      Survey

      User feedback.

      Patient Services Lead (CareConnections) 1 month

    5. 5

      Report

      Usage.

      Commercial Operations monthly

    6. 6

      Decide

      Invest or simplify.

      OGSIVEO Brand Lead 1 quarter

    First result
    1 quarter
    Cost
    Staff time only
    Owner
    OGSIVEO Brand Lead

    Smallest test

    Tag the links.

    Why it works

    Track sign-ups from each source (HCP office, support programme, website), add a QR code to the getting-started materials, and ask users which features help. Report usage with the support programme results.

    Simple tracking shows whether the tool deserves more investment.

    Risks and how to handle them

    • Low adoption

      Introduce it through the support programme call.

    Evidence

    • Your websiteBrand sites: ogsiveo.com offers a Spanish patient brochure, the OGSIVEO Digital Companion and a savings PDF; its Patient Mentor Program page says "the OGSIVEO Mentor Program is no longer being offered" but stays in the sitemap with its registration form text. gomekli.com has adult and children treatment pages, a find-a-doctor tool, and Spanish brochures and doctor discussion guides.Source
    • Your websiteogsiveo.com HCP site (sitemap checked October 23, 2026): sections for desmoid treatment, overview and data, dosing and management, patient support and access, practice resources, patient profiles, videos and Connect With Us; no page for payers, formulary decision-makers, pharmacists or GPOs. The Connect With Us form lists specialties "Oncology", "Surgery", "NP/RN/PA" and "Other". The access page describes SpringWorks CareConnections, Quick Start and Bridge programs, a commercial copay program, Field Access Managers and specialty pharmacy ordering.Source

03

How Programmable can help

Where an idea in this playbook is something Programmable builds or runs, it's listed here with what we'd do. Everything else is yours to run.

Have it built

ProgrammableAgency

1 of the 21 ideas are things Programmable builds and runs for its customers: pages, outreach, prospect lists, booking flows and monitors. Pick one, or send the whole list.

Prospect lists1The list compiled from public sources, verified, deduplicated and delivered to your CRM.

A 30-minute session with the engineer who would build it, not a sales call. You leave with a plan whether or not you hire us.

Book a working session

Usually live within days.

Tools for the rest

ProgrammableDigital

Show it, don't just describe it

These ideas need something to show: a demo, a video, an animation, graphics or a deck. Digital turns screenshots or the site into all of them, in the company's own brand.

Make a demo (opens programmable.digital in a new tab)
Website review of springworkstx.com More example playbooks and reviews

More growth playbooks

Other companies we have researched, each read from what they are hiring for.

  • Opal Security growth strategyAn AI-native access governance platform: visibility, just-in-time access, access reviews and policy as code for employees, service…22 growth ideas
  • Ralo growth strategyAn AI-native mortgage broker: one application goes to several lenders, software checks every quote for fees and negotiates, and a licensed…23 growth ideas
  • UpGuard growth strategyA Cyber Risk Posture Management platform: vendor risk, attack surface monitoring, workforce and shadow AI risk, Trust Exchange for…22 growth ideas
  • Nested Bean growth strategyGently weighted baby sleepwear: Zen Neo and Zen Swaddle swaddles, the Zen One transition swaddle, Zen Sack sleep sacks to 24 months, and…23 growth ideas
  • Lightspeed growth strategyA unified point of sale and commerce platform for retail, hospitality and golf: POS, payments, eCom, inventory, NuORDER wholesale, Capital…21 growth ideas
  • Marketing Automations growth strategyA certified ActiveCampaign consultancy (powered by Nimiety Marketing) that builds CRMs, follow-up automations and integrations from six…23 growth ideas
  • Camber growth strategyRevenue cycle management for specialty care: billing software with a payer rules engine trained on claims data, plus billing experts…21 growth ideas
  • Smartsheet growth strategyAn enterprise work management platform for projects, portfolios and workflows, now with Smart Assist, AI columns and dashboards, and an…20 growth ideas

See every playbook and website review

Independent research. Programmable wrote this playbook from public sources, as they stood on October 26, 2026, and cites them throughout. SpringWorks Therapeutics did not commission, review or endorse it, and Programmable is not affiliated with SpringWorks Therapeutics. Company and product names are trademarks of their owners, used only to identify them. The ideas are suggestions and opinion, not professional, legal or financial advice, and not statements about how SpringWorks Therapeutics runs its business.

Something wrong, or do you represent SpringWorks Therapeutics? Email [email protected] and we will correct it or take it down.

30/60/90 roadmap

What to focus on in each month, and the ideas that carry it.

  1. Days 1 to 306 ideas

    Payer and pharmacist front door, the GOMEKLI label link, disease page titles, the news menu, the closed mentor page and layout shifts.

  2. Days 31 to 6012 ideas

    Pull-through sheets, GOMEKLI territory kits, adult NF1 education, pharmacists, the managed-care evidence summary, Spanish support, pathologist education, the video library and advocacy partners; the find-a-doctor list, EU routing and the Digital Companion.

  3. Days 61 to 903 ideas

    Prepare access for a two-option market, plan the rare tumors HCP hub and start measuring support outcomes.

The research behind the plan

3 research areas, each summarised in a few lines. Open any of them for the full detail.

Customers

What customers say

Customers value approved options where there were none before. The most cited problem: rare diseases that take time to diagnose.

  • Personal support through CareConnections
  • Coverage delays for specialty medicines
  • In their words: “rare tumors”

Market

Competitive landscape

3 competitors compared: Immunome (varegacestat, investigational), Another approved MEK inhibitor and Surgery and other local treatments.

  • Gap to exploit: Owned channels for payers, pharmacists and GPOs
  • Immunome (varegacestat, investigational): Not approved; action date April 2027
  • Another approved MEK inhibitor: GOMEKLI is described by SpringWorks as the first and only approved for both adults and children

Hiring signals

SpringWorks is investing in access and field reach for both medicines.

  • Associate Director, Payer & Access Marketing - US Rare Tumors (OGSIVEO): Non-personal promotion for payers, pharmacists and GPOs. Ideas 1, 7, 10, 16.
  • Regional Business Director - West Region (OGSIVEO): Regional access and advocacy relationships. Ideas 7, 15.
  • Territory Business Manager - New Orleans (GOMEKLI): New territory; pediatric and adult neurology. Ideas 8, 9.

From the team that wrote this playbook

All products
  • ProgrammableAgencyWorking AI systems in days, not quarters (opens programmable.agency in a new tab)
  • ProgrammableInfoAn agent that finds, researches and asks firstNew accounts get 100,000 free enrichment credits with code BETA100K (opens programmable.info in a new tab)
  • ProgrammableDigitalScreenshots in, an animated product demo out (opens programmable.digital in a new tab)
  • ProgrammableWatchKnow the day a supplier falls out of compliance (opens programmable.watch in a new tab)
  • ProgrammableTalkGet registrants for your events, and know who’s coming (opens programmable.talk in a new tab)
  • ProgrammableMediaAn AI note taker, interpreter and webinar host for your calls (opens programmable.media in a new tab)
  • ProgrammablePageText what you need, your customer gets a page that works (opens programmable.page in a new tab)
  • ProgrammableCommunityForums with labelled AI members, never empty (opens programmable.community in a new tab)
ProgrammableMarketing
ExamplesLeaderboardsProductsTermsPrivacyCookiesDPALegalContact

© 2026 AI-Powered Growth Intelligence